Key Details
Price
$0.57Annual ROE
-32.08%Beta
1.55Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Oct 31, 1997Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium, PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success. Mr. Culley h.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Hsuan-Cheng Kuo - B. Riley Securities Joseph Pantginis - H.C.
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.03 per share a year ago.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C Wainwright Jack Allen - Baird Kristen Kluska - Cantor Fitzgerald Mayank Mamtani - B. Riley Sean McCutcheon - Raymond James Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call.
Start Time: 16:30 January 1, 0000 5:12 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill Howe - CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head, IR Conference Call Participants Joseph Pantginis - H.C. Wainwright Abigail Gray - Baird Kristen Kluska - Cantor Fitzgerald Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call.
Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms have reissued Buy/Outperform ratings on the stock, with price targets ranging from $4.00 to $7.00 a share. The company is partnered with Genentech around its main developmental program and that is targeting a large potential market.
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
FAQ
- What is the primary business of Lineage Cell Therapeutics?
- What is the ticker symbol for Lineage Cell Therapeutics?
- Does Lineage Cell Therapeutics pay dividends?
- What sector is Lineage Cell Therapeutics in?
- What industry is Lineage Cell Therapeutics in?
- What country is Lineage Cell Therapeutics based in?
- When did Lineage Cell Therapeutics go public?
- Is Lineage Cell Therapeutics in the S&P 500?
- Is Lineage Cell Therapeutics in the NASDAQ 100?
- Is Lineage Cell Therapeutics in the Dow Jones?
- When was Lineage Cell Therapeutics's last earnings report?
- When does Lineage Cell Therapeutics report earnings?
- Should I buy Lineage Cell Therapeutics stock now?